Oral or transdermal opioids for osteoarthritis of the knee or hip

BR da Costa, E Nüesch, R Kasteler… - Cochrane Database …, 2014 - cochranelibrary.com
Background Osteoarthritis is the most common form of joint disease and the leading cause
of pain and physical disability in older people. Opioids may be a viable treatment option if …

Oral or transdermal opioids for osteoarthritis of the knee or hip

E Nüesch, AWS Rutjes, E Husni… - Cochrane Database …, 2009 - cochranelibrary.com
Background Osteoarthritis is the most common form of joint disease and the leading cause
of pain and physical disability in the elderly. Opioids may be a viable treatment option if …

Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis

MF Williams, DA London, EM Husni… - Journal of Diabetes and …, 2016 - Elsevier
Background Observational studies have reported an association between type 2 diabetes
and osteoarthritis (OA) development and progression. However no systematic review of the …

Consensus on a core set of domains for psoriatic arthritis.

DD Gladman, PJ Mease, V Strand, P Healy… - The Journal of …, 2007 - jrheum.org
A psoriatic arthritis (PsA) module was convened at OMERACT 8 in order to achieve
consensus on the core domains that should be included in randomized controlled trials and …

Opioid therapy for treating rheumatoid arthritis pain

SL Whittle, BL Richards, E Husni… - Cochrane Database of …, 2011 - cochranelibrary.com
Opioid therapy for treating rheumatoid arthritis pain - Whittle, SL - 2011 | Cochrane Library Skip
to Content Cookies Our site uses cookies to improve your experience. You can find out more …

Breakthrough SARS–CoV‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis

CM Calabrese, E Kirchner, EM Husni… - Arthritis & …, 2022 - Wiley Online Library
Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …

Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations

A Ogdie, S Schwartzman, L Eder, AB Maharaj… - The Journal of …, 2014 - jrheum.org
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis that can lead to
decreased health-related quality of life and permanent joint damage leading to functional …

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries

F Lucasson, U Kiltz, U Kalyoncu, YY Leung… - RMD open, 2022 - rmdopen.bmj.com
Objectives Patient care can vary substantially by country. The objective was to explore
differences in psoriatic arthritis (PsA) across countries for disease activity, impact and …

Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis

LC Coates, A Kavanaugh, PJ Mease… - Arthritis & …, 2016 - Wiley Online Library
Objective To update the 2009 Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations …

[HTML][HTML] Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis

SE Nissen, ND Yeomans, DH Solomon… - … England Journal of …, 2016 - Mass Medical Soc
Background The cardiovascular safety of celecoxib, as compared with nonselective
nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain. Methods Patients who …